Literature DB >> 23651053

Targeting TGF-β signaling in cancer.

Lior H Katz1, Ying Li, Jiun-Sheng Chen, Nina M Muñoz, Avijit Majumdar, Jian Chen, Lopa Mishra.   

Abstract

INTRODUCTION: The transforming growth factor-β (TGF-β) signaling pathway has a pivotal role in tumor suppression and yet, paradoxically, in tumor promotion. Functional context dependent insights into the TGF-β pathway are crucial in developing TGF-β-based therapeutics for cancer. AREAS COVERED: This review discusses the molecular mechanism of the TGF-β pathway and describes the different ways of tumor suppression by TGF-β. It is then explained how tumors can evade these effects and how TGF-β contributes to further growing and spreading of some of the tumors. In the last part of the review, the data on targeting TGF-β pathway for cancer treatment is assessed. This review focuses on anti-TGF-β based treatment and other options targeting activated pathways in tumors where the TGF-β tumor suppressor pathway is lost. Pre-clinical as well up to date results of the most recent clinical trials are given. EXPERT OPINION: Targeting the TGF-β pathway can be a promising direction in cancer treatment. However, several challenges still exist, the most important are differentiating between the carcinogenic effects of TGF-β and its other physiological roles, and delineating the tumor suppressive versus the tumor promoting roles of TGF-β in each specific tumor. Future studies are needed in order to find safer and more effective TGF-β-based drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651053      PMCID: PMC3745214          DOI: 10.1517/14728222.2013.782287

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  177 in total

1.  SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells.

Authors:  Shigeo Matsuyama; Manabu Iwadate; Miki Kondo; Masao Saitoh; Aki Hanyu; Kiyoshi Shimizu; Hiroyuki Aburatani; Hiromu K Mishima; Takeshi Imamura; Kohei Miyazono; Keiji Miyazawa
Journal:  Cancer Res       Date:  2003-11-15       Impact factor: 12.701

Review 2.  TGF-β and its coreceptors in cancerogenesis: an overview.

Authors:  Nataša Todorović-Raković; Jelena Milovanović; Dragica Nikolić-Vukosavljević
Journal:  Biomark Med       Date:  2011-12       Impact factor: 2.851

Review 3.  TGF-beta signalling in colon carcinogenesis.

Authors:  Pavlos Lampropoulos; Adamantia Zizi-Sermpetzoglou; Spyros Rizos; Alkiviadis Kostakis; Nikolaos Nikiteas; Athanasios G Papavassiliou
Journal:  Cancer Lett       Date:  2011-10-07       Impact factor: 8.679

Review 4.  Inhibition of TGFβ signaling and its implications in anticancer treatments.

Authors:  I Calone; S Souchelnytskyi
Journal:  Exp Oncol       Date:  2012

Review 5.  Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update.

Authors:  Xuyu Zu; Qinghai Zhang; Renxian Cao; Jianghua Liu; Jing Zhong; Gebo Wen; Deliang Cao
Journal:  Cell Tissue Res       Date:  2011-08-16       Impact factor: 5.249

6.  Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.

Authors:  Laurens A van Meeteren; Midory Thorikay; Simon Bergqvist; Evangelia Pardali; Corrado Gallo Stampino; Dana Hu-Lowe; Marie-José Goumans; Peter ten Dijke
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

7.  TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: critical role of SMAD-2.

Authors:  Baljit Walia; Lixin Wang; Didier Merlin; Shanthi V Sitaraman
Journal:  FASEB J       Date:  2003-09-18       Impact factor: 5.191

8.  Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer.

Authors:  Tessy T Maliekal; Marie-Lue Antony; Asha Nair; Ramasamy Paulmurugan; Devarajan Karunagaran
Journal:  Oncogene       Date:  2003-07-31       Impact factor: 9.867

9.  Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.

Authors:  June-Chul Lee; Kyung-Mi Lee; Dong-Wan Kim; Dae Seog Heo
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

Review 10.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling.

Authors:  Rik Derynck; Ying E Zhang
Journal:  Nature       Date:  2003-10-09       Impact factor: 49.962

View more
  82 in total

1.  Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer.

Authors:  Yining Zhang; Zhaojin Yu; Qinghuan Xiao; Xuren Sun; Zhi Zhu; Junyan Zhang; Huimian Xu; Minjie Wei; Mingjun Sun
Journal:  Tumour Biol       Date:  2014-04-23

Review 2.  Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?

Authors:  Jente van Staalduinen; David Baker; Peter Ten Dijke; Hans van Dam
Journal:  Oncogene       Date:  2018-07-12       Impact factor: 9.867

3.  Blockade of TGF-β signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models.

Authors:  Daniel Newsted; Sunandan Banerjee; Kathleen Watt; Sarah Nersesian; Peter Truesdell; Levi L Blazer; Lia Cardarelli; Jarrett J Adams; Sachdev S Sidhu; Andrew W Craig
Journal:  Oncoimmunology       Date:  2018-11-20       Impact factor: 8.110

4.  Rab23 Promotes Hepatocellular Carcinoma Cell Migration Via Rac1/TGF-β Signaling.

Authors:  Li Zhang; Bingqiang Zhang; Wenxian You; Pan Li; Youlin Kuang
Journal:  Pathol Oncol Res       Date:  2018-09-06       Impact factor: 3.201

Review 5.  Tackling the cancer stem cells - what challenges do they pose?

Authors:  Diwakar R Pattabiraman; Robert A Weinberg
Journal:  Nat Rev Drug Discov       Date:  2014-07       Impact factor: 84.694

6.  Transforming growth factor β in cancer: Janus, the two-faced god.

Authors:  David Salomon
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

Review 7.  MicroRNAs as Potential Targets for Therapeutic Intervention With Metastasis of Non-small Cell Lung Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Mar-Apr       Impact factor: 4.069

Review 8.  Molecular targets and pathways involved in liver metastasis of colorectal cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Achim Krüger
Journal:  Clin Exp Metastasis       Date:  2015-06-24       Impact factor: 5.150

9.  Multispectral imaging reveals hyper active TGF-β signaling in colorectal cancer.

Authors:  Lei Yang; Zheng Liu; Jinjing Tan; Hongwei Dong; Xiaojing Zhang
Journal:  Cancer Biol Ther       Date:  2017-12-08       Impact factor: 4.742

10.  Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression.

Authors:  Hidetaka Ohnuki; Kan Jiang; Dunrui Wang; Ombretta Salvucci; Hyeongil Kwak; David Sánchez-Martín; Dragan Maric; Giovanna Tosato
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.